Neuroblastoma (NB) is a childhood cancer with unique traits influencing prognosis. Understanding its embryologic origin and utilizing advanced diagnostics like monoclonal antibodies can improve treatment outcomes.
Related Concept Videos
You might also read
Related Articles
Articles linked to this work by shared authors, journal, and citation graph.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2016
Neuroblastoma (NB) is a prevalent childhood cancer with variable prognosis.
NB exhibits distinct characteristics including age-dependent outcomes, metastasis at diagnosis, spontaneous regression, and immunogenicity.
Its embryologic origin from sympathetic nervous tissue and environmental influences on enzymatic activity are key aspects.
Purpose:
To review the unique characteristics of neuroblastoma.
To discuss factors influencing patient outcomes, including clinical and laboratory parameters.
To highlight advancements in diagnostic and therapeutic strategies for neuroblastoma.
Summary:
Prognosis is influenced by age, disease extent, primary site, histology, metastasis patterns, and immunologic factors.
Laboratory markers such as urinary catecholamines, ferritin, and neuron-specific enolase correlate with clinical course.
Monoclonal antibody techniques offer improved diagnostic and therapeutic potential.
In vitro soft agar assays predict drug sensitivity, aiding treatment selection.
Current therapies for disseminated NB are limited, but promising approaches include bone marrow transplantation and differentiation-inducing agents like retinoids.
Impact:
Enhanced understanding of neuroblastoma biology and clinical course.
Improved diagnostic accuracy through novel techniques like monoclonal antibodies.
Potential for more effective, targeted therapies for disseminated neuroblastoma.
Advances in predicting treatment response using in vitro assays.